| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $4.5M | -26.5% |
| Cost of Revenue | $2.0M | -36.7% |
| Gross Profit | $2.5M | -15.2% |
| R&D Expense | $2.3M | -28.3% |
| SG&A Expense | $15.7M | -14.6% |
| Operating Income | -$15.6M | +16.9% |
| Net Income | -$5.9M | +80.6% |
| EPS (Basic) | -$0.16 | +77.8% |
| EPS (Diluted) | -$0.16 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.6M | -8.7% |
| Short-term Investments | $7.5M | +0.0% |
| Accounts Receivable | $513K | -83.0% |
| Inventory | $6.2M | +6.5% |
| Current Assets | $10.5M | -50.7% |
| Total Assets | $15.1M | -46.9% |
| Current Liabilities | $13.2M | -43.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$8.1M | +51.4% |
| Capital Expenditures | $12K | -94.8% |
| Investing Cash Flow | $7.3M | +41.2% |
| Financing Cash Flow | $468K | -95.4% |
| Free Cash Flow | -$8.1M | +51.9% |
| +77.8% |
| Total Liabilities |
| $14.9M |
| -41.3% |
| Stockholders' Equity | $250K | -92.1% |